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Abstract
Bacterial vaginosis is a prevalent state of dysbiosis of the vaginal microbiota with wide-rang-
ing impact on human reproductive health. Based on recent insights in community ecology of
the vaginal microbiome, we hypothesize that sustained vaginal DL-lactic acid enrichment
will enhance the recruitment of lactobacilli, while counteracting bacterial vaginosis-associ-
ated bacteria. We therefore aimed to develop an intravaginal device that would be easy to
insert and remove, while providing sustained DL-lactic acid release into the vaginal lumen.
The final prototype selected is a vaginal ring matrix system consisting of a mixture of ethyl-
ene vinyl acetate and methacrylic acid-methyl methacrylate copolymer loaded with 150 mg
DL-lactic acid with an L/D-lactic acid ratio of 1:1. Preclinical safety assessment was per-
formed by use of the Slug Mucosal Irritation test, a non-vertebrate assay to evaluate vaginal
mucosal irritation, which revealed no irritation. Clinical safety was evaluated in a phase I
trial with six healthy nulliparous premenopausal volunteering women, with the investiga-
tional drug left in place for 7 days. Colposcopic monitoring according to the WHO/CONRAD
guidelines for the evaluation of vaginal products, revealed no visible cervicovaginal mucosal
changes. No adverse events related to the investigational product occurred. Total release
from the intravaginal ring over 7 days was estimated through high performance liquid chro-
matography at 37.1 (standard deviation 0.9) mg DL-lactic acid. Semisolid lactic acid formu-
lations have been studied to a limited extent in the past and typically consist of a large
volume of excipients and very high doses of lactic acid, which is of major concern to muco-
sal safety. We have documented the feasability of enriching the vaginal environment with
pure DL-lactic acid with a prototype intravaginal ring. Though the efficacy of this platform
remains to be established possibly requiring further development, this approach may offer a
novel avenue to modulate and protect the vaginal microbiota.
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Introduction
Dysbiosis of the human vaginal microbiome has long been recognized and is basically under-
stood as a prolonged shift away from a Lactobacillus-dominated microbiota [1]. While encom-
passing different community states deplete of lactobacilli [1], our understanding of the pivotal
role of the vaginal microbiome in health and disease primarily derives from a vast body of evi-
dence on adverse health outcomes associated with bacterial vaginosis (BV), a community state
characterized by a highly diverse, anaerobic microbiota thriving in a drastically different vagi-
nal environment [2,3].
Historically, BV has received ample attention as a clinical entity. Though most often asymp-
tomatic [4], symptomatic BV still is a leading cause of vulvovaginal complaints, typically
involving profuse, foul-smelling vaginal discharge. BV symptoms often resolve spontaneously,
however also frequently tend to recur over an extended period of time [5,6], negatively impact-
ing on women’s intimate, social, and professional relationships [7,8]. Compelling epidemiolog-
ical evidence has further shown that regardless of symptoms, as a state of dysbiosis, BV is
associated with adverse reproductive health outcomes, including adverse pregnancy outcomes
such as preterm birth, and acquisition of sexually transmitted infections including HIV and
HPV [9–11]. Recently, evidence is also mounting that BV might negatively impact human
reproduction [12–14].
Understanding community ecology and community dynamics of the vaginal microbiome
may therefore offer an avenue to modulate and protect the vaginal microbiota, which, provided
feasible, may have a considerable impact on preventing disease in women, their partners, and
their offspring.
In the human vagina, the epithelium enriches the lumen with glycogen [15], as the primary
carbon source to the resident lactobacilli, free vaginal glycogen content strongly correlating
with Lactobacillus dominance [16–18]. Vaginal glycogen enrichment is considered a primary
driving force that allows the human vagina to exert strong selective pressure in allowing bacte-
ria to reside in this microenvironment [18–20]. In the Human Microbiome Project it was
indeed shown that of all body sites accounted for, the vagina shows the lowest species diversity
at the currently handled phylogenetic resolution level [21]. Merely four species belonging to
the large and phylogenetically diverse Lactobacillus genus are found to dominate the vaginal
microbiome in majority of women, i.e. L. crispatus, L. iners, L. jensenii, and L. gasseri, most
often without displaying co-dominance and further accompanied by a number of unrelated
species mostly occurring at low abundances [1]. Vaginal lactobacilli are incapable of glycogen
fermentation however [22], glycogen breakdown presumably involving human α-amylase
[23,24] and at least one other, as yet uncharacterized vaginal enzyme [25], generating the glu-
cose oligomers maltose, maltotriose, and maltotetraose as the direct carbon sources to the resi-
dent community. Under the physiological high carbon dioxide and low oxygen levels that
prevail in the vaginal environment, the vaginal Lactobacillus-dominated microbiota in turn
produce high levels of lactic acid (mean = 1.0% w/v, SD 0.2) in a racemic mixture of D- and
L-isomers, thereby acidifying the vagina to an average pH of 3.5 (standard deviation (SD) 0.3,
range 2.8–4.2) [26]. L. iners differs from the other vaginal key species, as it lacks the gene cod-
ing for D-lactate dehydrogenase, yet is capable of converting glucose to pyruvate and pyruvate
into L-lactic acid [27].
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Lactic acid is a lipid-soluble membrane-permeant carboxylic acid that in accordance with
its pKa value of 3.9, is predominantly present in the acidic vaginal environment (average pH
3.5, SD 0.3, range 2.8–4.2) as protonated lactic acid and to a much lesser extent as the unproto-
nated lactate [11,26,28,29]. It is generally assumed that by creating an acidic environment
through lactic acid production, vaginal lactobacilli preserve their own dominance in this habi-
tat, supported by Lactobacillus growth characteristics in vitro [30]. Although difficult to prove
this mechanistic view in vivo, free glycogen concentration is significantly positively associated
with low pH [16], further corroborating niche construction dynamics as set forth.
Lactic acid-associated vaginal acidity is also considered a primary physicochemical barrier
to colonisation by invading pathogens, as documented for instance for HIV-1 [29] and Chla-
mydia trachomatis [31]. In addition, lactic acid as such, has recently emerged as a potent innate
immune factor displaying a wide array of antimicrobial and immunomodulatory effects, not
explained by its acidifying effect [32]. O’Hanlon et al documented in a pioneering in vitro assay
that while acidity alone modestly reduced the viability of seventeen BV-associated key bacteria,
lactic acid at physiological concentrations and at physiological pH, also exerted strong direct
microbicidal activity against all BV-associated bacteria included [28]. Similarly, Aldunate et al
showed modest reductions of HIV-1 infectivity resulting from acidification, yet potent virucidal
activity against HIV-1 by L-lactic acid at physiological concentrations at low pH [29]. Evidence is
further building that lactic acid displays a wide array of immunomodulatory effects, further
enhancing the vaginal mucosal innate and adaptive response to pathogen challenge [11,32].
Noteworthy, Witkin et al recently revealed that the key vaginal Lactobacillus species differentially
express the D- and L-lactate isomers, and pointed at the putative importance of the L/D-lactic
acid ratio to vaginal immune homeostasis [32,33], an issue that warrants further scrutiny.
From these recent insights, several putative prebiotic strategies to long-term protection of
the vaginal microbiome emerge, including vaginal replenishing with glycogen and glucose olig-
omers. We hypothesize that intravaginal lactic acid administration may also provide an avenue
to the sustainment of an advantageous vaginal microbiome by creating an environment that
enhances the recruitment of lactobacilli, while counteracting BV-associated bacteria. Lactic
acid gels are commercially available and haven proven particularly useful in our experience,
yet also have several disadvantages, such as frequent administration possibly leading to poor
compliance, and leakage, a side-effect that is particularly undesirable in women with a history
of vaginal discharge. We therefore aimed to develop an intravaginal device that would be easy
to insert and remove, while providing sustained DL-lactic acid release into the vaginal lumen.
Methods
Vaginal ring manufacture
Ethylene vinyl acetate (EVA) was chosen as the primary copolymer, considering its established
use for intravaginal delivery systems. A pure EVA matrix did not allow us however to load a
sufficient amount of lactic acid and to obtain the desired release profile. Various polymer
blends were subsequently developed through hot-melt extrusion and explored with regard to
the overall study purpose. The final prototype selected for clinical study is a vaginal ring matrix
system (external diameter 54 mm, thickness 4mm) consisting of a mixture of EVA 28 (28% w/
w vinyl acetate, 72% w/w ethylene) (Celanese, EVA Performance Polymers, Edmonton, US)
and the methacrylic acid-methyl methacrylate copolymer (1:1) Eudragit L100 (Evonik Indus-
tries AG, Darmstadt, Germany) in a ratio of 80.5/19.5 (% w/w), loaded with 150 mg DL-lactic
acid (Fagron, Waregem, Belgium) with an L/D-lactic acid ratio of 1:1.
EVA 28 and Eudragit L100 were mixed with the lactic acid in a planetary mixer. When
homogeneously blended, the mixture was extruded using a co-rotating twin screw extruder
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(Haake MiniMHE, Thermo Electron, Karlsruhe GmbH, Germany) at 90°C and the extrudate
was subsequently injection moulded (Haake Mini Jet, Thermo Electron, Karlsruhe GmbH,
Germany) into a ring mould at 800 bar and room temperature with a post pressure of 400 bar.
Finally the ring was removed from the mould. The rings were GMP manufactured and individ-
ually packed in Alu/Alu sealed bags.
In vitro release assessment
Basic screening of in vitro lactic acid release without accounting for vaginal buffering capacity
was performed by placing ring segments of approximately 4.5 cm in a sterile recipient with
5mL demineralized water and incubated at 37°C for 10 days. The medium was replaced every
24 hours and the pH was measured daily for 10 consecutive days prior to replacement of the
medium. With the final investigational product, pH of the medium ranged between 2.9 and 3.7
during this period.
Preclinical safety assessment
Preclinical safety assessment was performed by use of the Slug Mucosal Irritation (SMI), a
non-vertebrate assay to evaluate mucosal irritation that we have developed [34] and previously
used for various vaginal products, also in comparison with the rabbit vaginal irritation test
[35–37]. Briefly, both the matrix system with (formulation A) and without racemic lactic acid
(formulation B) were tested with the SMI. Drum dried waxy maize (DDWM) starch treated
slugs were used as negative controls (NC), while slugs treated with DDWM/sodium lauryl sul-
phate (DDWM/SLS, 80:20) were used as positive controls (PC). The slugs were placed daily on
20 mg test substance (formulation A, formulation B, NC, and PC respectively) in a Petri dish
for 30 minutes a day for 5 consecutive days. For each test substance five slugs were used.
The amount of mucus produced by the slugs during each contact period was measured by
weighing the Petri dish with the test substance before and after the 30-minute contact period.
Mucus production (MP) was expressed as percentage (w/w) of the body weight of the index
slug. After each 30-minute contact period, the slugs were placed on a membrane filter (cellulose
acetate 0.45 μm, Sartorius, Germany) moistened with 2 mL PBS buffer solution in a Petri dish
until the next contact period. The irritation potency of the formulations is estimated by the
total mucus production during the 5-day testing period (sum of proportional mucus mass pro-
duced during each 30-minute contact period). The assay distinguished between four irritation
categories: no irritation (total MP 7%), mild (7%> total MP 12%), moderate (12%> total
MP 20%) and severe irritation (total MP> 20%).
Lactic acid assay
Lactic acid load of the intravaginal ring was determined using a validated high performance liq-
uid chromatography (HPLC) method. Briefly, following dissolution of the ring in chloroform,
lactic acid was extracted with an aqueous pH 7 buffer. The HPLC system consisted of a Prevail
Organic Acid column (250 x 4.6 mm; 5 μm) and a guard column. The mobile phase consisted
of a 25 mM potassium platform buffer (pH 2.5). The pump flow was set at 1 mL per minute.
The HPLC system consisted of a water Alliance 2695 separation module and a Photodiode
Array detector and the detection wavelength was 220 nm. The eventual prototype was devel-
oped at Ghent University. However, for production of the intravaginal delivery system under
GMP conditions intended for clinical investigation, license was given to a private, university
spin-off company, SEPS Pharma (currently AmatsiSEPS), for manufacture of the investiga-
tional product for study purposes.
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Mechanical testing
Maximum load, tensile strain at maximum load and Young’s modulus ware determined just
after manufacturing and after lactic acid release using a tensile strength machine (Ametek LF
Plus, Lloyd Instruments, Heaceham, UK) at room temperature and 65% relative humidity.
Microbiological analysis
Incubation of the rings before sealing revealed no growth on Tryptone Soya Agar and no pres-
ence of Staphylococcus aureus, Pseudomonas aeruginosa nor Candida albicans.
Subject recruitment
For the first-in-human phase I clinical trial, six healthy nulliparous premenopausal volunteer-
ing women (median age 25 years, range 23 to 32 years) were recruited by the DRUG Research
Unit Gent, a phase 0-I-II clinical trial unit (see study flow and ethical considerations below).
Screening examinations included a standardized questionnaire on medical and gynaecologic
history. Prior to enrolment all subjects screened negative on pregnancy testing. Volunteers
were also subjected to a thorough gynaecological assessment to ascertain the absence of vulvar,
vaginal, and cervical anomalies and the absence of pelvic floor dysfunction.
None of the subjects had a history of uterine, vaginal, or vulvar surgery, nor a history of vag-
inal infectious disease, except for occasional Candida vulvovaginitis. None of the subjects
declared to have ever used intravaginal products or devices except for tampon use and occa-
sional use of a topic antifungal drug preparation. A vaginal swab specimen (Eswab™, Copan,
Brescia, Italy) was obtained from the midportion of the vaginal vault and served for Nugent
scoring [38] and culture. All subjects eventually included showed a Lactobacillus-dominated
microbiota with Nugent scores between 1 and 3, while yeast culture was negative in all subjects.
The presence of Chlamydia trachomatis was ruled out by use of an endocervical swab specimen
(UTM™, Brescia, Copan, Italy).
All volunteering women included used a combined oral contraceptive (COC) pill upon
inclusion and were instructed to continue their COC for the duration of the study to avoid
withdrawal bleeding. Study subjects were further asked to abstain from penetrative sexual con-
tact and to avoid the use of any vaginal product or device for at least 72 hours and 7 days
respectively, before insertion of the vaginal ring. Concomitant drug use was not allowed.
Ethical considerations and study flow
All study subjects gave their oral and written informed consent to participate in the study. Sub-
jects were compensated for their time and expenses related to participation in the study. The
study was conducted in accordance with the tenets of the Declaration of Helsinki and current
ICH-GCP guidelines. The principal investigator (PI) holds a GCP certificate. The study has
been registered with the European Clinical Trials Database (EudraCT 2013-001120-19) and
with the U.S. National Institutes of Health ClinicalTrials.gov registry (identifier
NCT02314429).
Initial ethical approval was obtained from the Ghent University Institutional Review Board
(IRB) on April 4 2013 (reference EC2013/088). The Federal Agency for Medicines and Health
Products (FAGG) labelled the investigational product as a study drug (rather than a device) and
requested additional technical and preclinical data, owing to which approval for safety evaluation
was granted one year later, on April 25 2014, endorsed by the IRB on April 29 2014. Specifically,
the FAGG gave conditional approval for a staged approach, allowing us to conduct the study in
two healthy volunteers, further study conduct depending on intermediate reporting.
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After revision of the original files for which approval was granted, a final protocol (S1–S3
Files) and a final informed consent form (S4 File) were submitted to the IRB as an amendment
to the original files, which the IRB approved on July 15 2014. The final protocol and the final
informed consent form are available as Supplementary Materials (S1 and S4 Files, respectively)
accompanying this paper.
The study flow is presented in detail as a TREND [39] flowchart (Fig 1).
Following final, conditional approval DRUG Research Unit Gent started recruiting volun-
teers. DRUG is an accredited phase 0-I-II clinical trial unit that was positively evaluated by the
US Food and Drug Administration. DRUG maintains a database with more than 2,000 volun-
teers willing to participate in clinical trials, from which eligible women were invited through e-
mail until six candidate study participants were recruited from mid-July to mid-August 2014.
Six candidate study participants gave their informed consent on August 21 2014, following
general health screening by a clinical trial physician of DRUG and a gynaecological screening
exam by the principal investigator (PI). Of these, two subjects were withheld to enter the first
stage of the trial, while another two subjects served as back-up study subjects allowing replace-
ment of subjects when needed.
The actual trial with insertion of the investigational product and follow-up as detailed
below, took place within the clinical facility of the DRUG Research Unit Gent at Ghent Univer-
sity Hospital from September 8 to September 15 2014. An intermediate report based on the
study data obtained during this stage was send to the Federal Agency for Medicines and Health
Products (FAGG) and to Ghent University Institutional Review Board (IRB) September 19
2014. The FAGG and the IRB subsequently granted their approval for the further study con-
duct on September 22 and 23 2014, respectively.
Accordingly, from late September until the end of October 2014, DRUG re-invited eligible
women through a mailing, until twelve candidate study participants were recruited. Eventually,
six candidate study participants gave their informed consent on November 17 and another six
on November 20 2014, following general health screening by a clinical trial physician of DRUG
and a gynaecological screening exam by the PI. Of these, four subjects were withheld to enter
the second stage of the trial, while another four subjects served as back-up study subjects allow-
ing replacement of subjects when needed. One subject was replaced by a back-up study subject
immediately before investigational drug administration, as she disclosed sexual intercourse less
than 12 hours before the planned intravaginal device insertion. Subject AN006 reported a
cough during the study, was subsequently diagnosed with bronchitis, and was therefore fol-
lowed until cure was established until mid-January 2015.
On February 5 2015 we submitted our final report along with the adverse event (AE) list (S5
File) to the Federal Agency for Medicines and Health Products (FAGG) and to Ghent Univer-
sity Institutional Review Board (IRB). On September 29 2015 Bimetra Clinical Research Centre
Ghent conducted a monitoring assessment of all study files, following which a Declaration of
the End of Trial Form was submitted to the IRB and the FAGG.
Study procedures
The investigational device, as specified above, an intravaginal polymer ring loaded with 150 mg
DL-lactic acid in a 1:1 racemic mixture, was inserted into the upper vagina by the PI, after the
volunteer assumed a classic dorsal lithotomy position, left in place for precisely 7days, and
removed by the PI at the occasion of the final safety assessment.
Colposcopic evaluation of the cervix and the vagina was performed by use of a stationary
colposcope (Carl Zeiss, Oberkochen, Germany) at magnification x10, after placement of a dis-
posable, sterile, transparent plastic speculum without lubrication. Colposcopy findings were
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recorded according to the WHO/CONRAD guidelines for the evaluation of vaginal products
[40]. Colposcopic evaluations were performed one hour following insertion of the device,
respectively after two, four, eight and 24 hours, and again after seven completed days.
Though no effect on vaginal pH was aimed for, nor expected, we wanted to ascertain that
the vaginal pH would not drop below the physiological range. Accordingly, vaginal pH was
assessed by use of a pH-Fix indicator strip (Machery-Nagel, Düren, Germany) after placement
of disposable, sterile, transparent plastic speculum without lubrication, allowing to monitor the
pH between a range of 3.1 to 8.3 in 0.4 increments. Vaginal pH measurements were performed
each 30 minutes during the first four hours following placement of the device, each hour for
the following four hours, and again after seven completed days.
On each occasion of an investigational act, naked eye inspection of the vulva, vagina, and
cervix was also performed. In between these investigations, the volunteer was allowed to walk
around during the first day of the study and to resume normal daily activities during the fur-
ther conduct of the study.
Adverse event reporting
During the first 8 hours after insertion of the vaginal ring, volunteers were not allowed to leave
the clinical trial unit, with the PI and two clinical trial physicians in place. Volunteers were
asked to spontaneously report any potential adverse event (AE), but were also actively asked
for AEs before each investigational act. In case an AE was reported that did not prompt any
action during this phase, follow-up was secured through telephone contacts during the further
course of the study. Volunteers were also asked to record any potential AE in a diary during
the entire study course. The final AE list is available through the Supplementary materials (S5
File) accompanying this paper.
Results
Intravaginal ring characteristics
Based on HPLC analysis, the mean lactic acid load of the intravaginal ring following manufac-
ture varied between 90 and 110% of the label claim (150 mg).
Incubation of the intravaginal ring (n = 3) in demineralized water at 37°C for 24 hours
showed release of on average 9.20 mg (SD 0.52), corresponding to an estimated 6.13% (SD
0.35) of the overall lactic acid load.
The maximum load after manufacturing and after leaching of lactic acid was 39.6 N (SD
1.6) and 43 N (SD 2.3), respectively. The tensile strain at maximum load was 401.2 and 373.2
after manufacturing and leaching of lactic acid, respectively. The Young’s modulus was 115.4
Pa (SD 23.1) and 88.3 Pa (SD 7.3) after manufacturing and leaching, respectively.
Preclinical safety assessment
Slugs exposed to the intravaginal ring matrix with and without DL-lactic acid (1:1) produced a
minimal amount of mucus during contact, with a total MP of 3.3% w/w of body weight (SD
0.9) and 3.8% w/w of body weight (SD 1.6) on average for slugs treated with formulation A and
B, respectively, and hence the investigational product produced no irritation in the SMI test
Fig 1. TREND study flowchart of the phase I trial. Legend: *patients were selected based on chronological
order of enrolment. To ascertain that the study could take place as planned, an excess number of eligible
study participants were recruited. Similarly, at each stage two back-up study subjects were standby to allow
for rapid replacement of subjects, as proved necessary in one case, who violated the prohibitions explained
in the informed consent form.
doi:10.1371/journal.pone.0153441.g001
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(total MP 7%). This is comparable with the total amount of mucus produced by the negative
control slugs (5.6% w/w of body weight, SD 1.3). Positive control slugs on the other hand
showed a high total MP (23.7% w/w of body weight, SD 3.6) indicating severe irritation (total
MP> 20%).
Safety and tolerability assessment in healthy volunteers
All volunteering women enrolled (n = 6) completed the study. Naked eye inspection did not
reveal any vulvar lesions during the 7-day study course. Similarly, colposcopic examination of
the vagina and the cervix did not show any sign of epithelial disruption, oedema, colour
change, or subepithelial bleeding as the vaginal ring was in place. In one subject, at some point
in time during the initial safety assessment phase, insertion of the speculum provoked a tran-
sient bleeding at the cervical ectropion site, however without hindering colposcopic assess-
ment. Vaginal pH at initial assessment ranged between 3.1 and 4.3 and remained largely
constant throughout the initial 8 hour safety monitoring phase, except in the subject with cervi-
cal ectropion bleeding who maintained a pH of 4.7. At the final safety assessment of the 7-day
study course, vaginal pH in all subjects ranged between 3.5 and 4.3.
A total of 11 adverse events (AEs) were reported by four subjects (S5 File). All AEs were
considered to be unrelated to the investigational device and hence required no action with
regard to the conduct of the study. Seven AEs did concern the pelvis. In subject AN001 a break-
through bleeding following continuous COC use occurred on day 7, first noticed two hours
before removal of the ring. In subject AN002 mild bleeding of the cervical ectropion was
noticed following the first speculum examination, which appeared to have completely resolved
during the colposcopic assessment 8 hours post-insertion. The latter subject also reported a
mild pressure sensation in the lower abdomen 10 hours after placement of the ring, which she
ascribed to the repeated gynaecological examinations during that day. Subject AN005 reported
two transient episodes of discomfort over the posterior vaginal vestibular area on day 1, which
she attributed to the repeated speculum insertions. Finally, subject AN006 reported a vaginal
foreign body sensation 12 hours after insertion of the device, which she also ascribed to the
investigational procedures. Hence, except for the breakthrough bleeding in subject AN001, all
pelvic AEs occurred during the first day of the study involving twelve speculum examinations
during the first 8 hours and were considered to be procedure-related. Consequently, no such
pelvic AEs were reported during the further study course.
At the end of the study, all study subjects were briefly asked for their experience with partici-
pating in the study and the acceptability of the intravaginal ring. All subjects reported mild to
moderate vaginal discomfort associated with the repeated safety assessments on day 1. Simi-
larly, all subjects confirmed not to have experienced any discomfort during the further study
course with the vaginal ring in place, which they considered highly acceptable.
Lactic acid release
HPLC analysis performed immediately following clinical testing revealed that a mean of 37.1
mg (SD 0.9) DL-lactic acid was released from the vaginal ring over the 7-day study course, indi-
cating that the vaginal ring load might enrich the vaginal environment with DL-lactic acid for a
considerably longer period then was considered in the present study.
Discussion
We developed an intravaginal device ensuring continuous slow release of DL-lactic acid into
the vaginal environment from the hypothesis that sustained lactic acid enrichment will
enhance the recruitment of lactobacilli, while counteracting bacterial vaginosis-associated
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bacteria. The final prototype selected is a vaginal ring matrix system consisting of a mixture of
ethylene vinyl acetate and a methacrylic acid-methyl methacrylate copolymer loaded with 150
mg DL-lactic acid with an L/D-lactic acid ratio of 1:1. DL-lactic acid release from the intravagi-
nal ring during a 7-day period in vivo was estimated through HPLC analysis at 37.1 mg (SD
0.9). While we did not assess DL-lactic acid release in vivo at shorter durations, and hence are
unable to document the release profile in detail, the preclinical in vitro assessment did not
show a significant burst release with an estimated 6.13% (SD 0.35) of the overall lactic acid load
released over the first 24 hours. Indirect monitoring of lactic acid release in an aqueous
medium through pHmeasurement for 10 consecutive days was also consistent with continuous
slow release during this period. No adverse effects were observed during preclinical testing
with the slug mucosal irritation assay, nor in a phase I clinical trial with 6 healthy volunteers.
Novel approaches in modulating and protecting the vaginal microbiota are particularly
appealing for a number of reasons.
First, such approaches might provide health care providers with an acceptable means in
treating patients with recurrent bacterial vaginosis (BV), a particularly prevalent and frustrat-
ing condition negatively impacting on women’s quality of life. Historically, and particularly
due to the emphasis on Gardnerella vaginalis as the presumed causative agent since the 1950s,
BV has been considered as an infectious disease which has led to a number of clinical trials
with a wide array of antibiotics [41]. Two hallmark studies, with metronidazole [42] and clin-
damycin [43], respectively, eventually set the scene for current treatment guidelines [41]. Basi-
cally, antibiotic treatment of BV is understood to clear the vaginal niche from its highly diverse
polymicrobial community, rapidly leading to symptomatic relief, while allowing lactobacilli to
re-occupy this vacated niche. High recurrence rates are however observed with standard antibi-
otic treatment [5], even after a prolonged treatment course of 16 weeks [44].
From human microbiome research in recent years, the notion of a ‘bacterial community as
a pathogen’ emerged as a novel concept in microbial pathogenesis, in which a conserved micro-
bial assemblage, rather than any one specific member, contributes to disease [45]. Accordingly,
when considering the pathogenicity of the microbiome, it might be better to focus on bacterial
community ecology and dynamics [46]. As a community state, BV is actually a rather stable
community disturbance presumably also due to biofilm formation [47] and community stabil-
ity should therefore not be misconstrued with healthy or advantageous microbiota [48]. Hence,
novel approaches as proposed in the current study, that alter the vaginal niche through a prebi-
otic approach enhancing vaginal re-colonisation with lactobacilli are therefore not confined to
recurrent symptomatic BV, but also have a tremendous potential in preventing bacterial vagi-
nosis-associated disease in women, their partners, and their offspring.
A particularly interesting alternative approach is the administration of probiotic lactobacilli,
subsequent evidence-based assessments [49–52] all precautiously pointing at positive proof-of-
concept in the absence of sufficiently strong evidence at present in recommending probiotics
in the treatment of recurrent BV. Recent whole genome sequencing approaches now allow for
unprecedented comprehensive screening of probiotic functionality of selected vaginal key Lac-
tobacillus species such as selected L. crispatus strains [53–56], than was previously achieved
with cultured isolates, and therefore provide another promising avenue for the development of
vaginal probiotics. Finally, synbiotic approaches, combining probiotics and prebiotics, are
another therapeutic and prophylactic perspective in modulating and protecting the vaginal
microbiota
The prebiotic approach has been previously explored, especially with regard to lactic acid.
Holst and Brandberg reported on a small, non-controlled trial in 10 pregnant women with inci-
dent BV who administered a vaginal lactic acid gel intermittently for 8 weeks [57]. The authors
reported that all women reverted to a lactobacilli-dominated after 2 days of treatment, 8
Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release
PLOS ONE | DOI:10.1371/journal.pone.0153441 April 19, 2016 10 / 15
women maintaining clinical and microbiological cure at the end of the trial [57]. Andersch
et al, recruited 42 women with recurrent BV (3 or more documented episodes during a
12-month period prior to enrolment) and initially treated all women with vaginal lactic acid
gel, administered for 7 consecutive days at night [58]. Study participants were subsequently
randomized in two arms in a double-blinded fashion and instructed to administer the vaginal
lactic acid gel or an identical placebo for 3 consecutive days after menstruation or withdrawal
bleeding for 6 months. At the end of the trial, clinical cure was documented for 88.2% (15/17)
of women in the lactic acid group versus 10% in the placebo group (1/10), and microbiological
cure was found with 87.5% (14/16) of patients with the active drug versus 10% in the placebo
group (1/10) [58]. Even when accounting for substantial drop-out in this study, continued
intermittent lactic acid treatment therefore appears promising in long-term treatment of BV. It
should be acknowledged however, that the investigational product in the latter study actually
consisted of lactic acid (5% w/v) as well as glycogen (0.1% w/w). Albeit not addressed by the
authors, glycogen may have contributed to the observed effects. In a large randomized, double-
blinded, three-arm comparison of a single course of oral metronidazole for 7 days, lactic acid
(100 mg) vaginal suppositories for 7 days, and placebo treatment for the treatment of incident
BV, Boeke et al found that cure rates with lactic acid suppositories were not different from pla-
cebo and significantly less effective than metronidazole at 4 weeks and 3 months, respectively
[59]. Though the latter study was rigorously designed, the authors did not provide details on
the lactic acid suppository manufacturing, which may be critical to lactic acid release, which
was also not reported. Finally, in an open-labeled study, Decena et al, found vaginal lactic acid
gel, oral metronidazole, and a combination of those to be equally effective in short-term cure of
incident BV [60]. Hence, while disparate results have been obtained in the treatment of inci-
dent BV, one study [58] does provide preliminary evidence on the potential of lactic acid
(though combined with glycogen) in modulating and protecting the vaginal microbiota for a
prolonged period of time, and therefore warrants further scrutiny.
A major advantage of the polymer device presented here involves the easiness to insert and
remove, while avoiding administration of semisolid vaginal formulations such as suppositories
and gels, which are of concern because of several reasons. An obvious disadvantage of such for-
mulations is the frequent administration, limited residence time, and significant leakage from
the vagina [61]. Secondly, the safety of such extremely high doses of lactic acid, relative to phys-
iological concentrations, has not been established. Thirdly, while vaginally applied products
have been a general issue of concern since the nonoxynol-9 story [62–64], recent systems biol-
ogy approaches have further increased such concern with regard to microbicides and even to
vaginally applied excipients in microbicide formulations, transcriptomic studies revealing sig-
nificant mucosal and immune toxicity with commercial and investigational formulations previ-
ously considered safe [65–67]. Intravaginal devices such as intravaginal rings allow to
circumvent such toxicity by slowly releasing only the desired drug, which in this case is even a
primary physiological constituent of this niche.
While we have therefore shown at present the feasability of enriching the vaginal environ-
ment with DL-lactic acid with a prototype intravaginal ring, further development of the present
invention is warranted. First, the ethylene vinyl acetate/methacrylic acid-methyl methacrylate
matrix we used showed significantly less rigidity compared to presently available intravaginal
ring systems. While this may add to patient comfort, it also increases the risk for expulsion of
the intravaginal ring [68]. Second, while we aimed to mimic physiological DL-lactic acid con-
centrations present with lactobacilli-dominated microbiota, we are uncertain at present
whether the release obtained will be sufficient to obtain the desired prebiotic effect. Third, as
mentioned above, it was recently suggested that the L/D-lactic acid ratio may also be of impor-
tance to vaginal immune homeostasis [32,33], and therefore the L/D-lactic acid ratio with our
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system might be optimized. Here, we handled an L/D-lactic acid ratio of 1 which is close to
what is observed with L. crispatus and significantly lower than the L/D-lactic acid ratio
observed with a L. iners-dominated microbiome, suggesting that an L/D-lactic acid ratio of 1
might actually be quite favourable [69].
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